Q-omics provides the consensus-scored RBPJP7 profile across patient tissues and cancer cell-line models. RBPJP7 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RBPJP7 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, RBPJP7 RNA expression shows 5,118 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, ESCA, and STAD as cancer lineages where RBPJP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBPJP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBPJP7 survival associations across molecular data types. RBPJP7 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBPJP7 RNA expression–survival associations across cancer types. High RBPJP7 expression shows unfavorable associations in UCEC, BLCA, ACC, PCPG, SKCM and THYM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RBPJP7 RNA expression.
This table summarizes RBPJP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RBPJP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBPJP7 shows higher tumor expression in ESCA. The ESCA box plot shows higher RBPJP7 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p < 0.001).
This table shows molecular features associated with RBPJP7 in patient tissues and cancer cell lines. In patient samples, RBPJP7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
